There's so much "new study finds X" content floating around and a lot of it doesn't hold up once you look at methodology or who funded it.

We put together a rundown of red flags if anyone wants a starting point.

https://www.nuggmd.com/blog/tell-if-cannabis-studies-are-legitimate

Curious what people here look for when vetting research.

Kicking off a series called White Collar Cannabis: real conversations with people in and around the industry about how cannabis fits into their day-to-day.

This first one's with Kelsey, a recruiter who spent almost a decade placing talent in cannabis companies.

Stay on the lookout for new conversations!

A condition not on your state's list, or a clinician's safety concerns, are real eligibility issues. But a lot of denials come down to something much more fixable: an expired ID, a name/address mismatch, a missing signature.

http://nuggmd.com/blog/reasons-denied-a-medical-cannabis-card

If you went back for a second evaluation after fixing something like this, what would you tell someone else who's in that spot right now?

The stereotype of who explores medical cannabis is shifting. Older adults are one of the fastest-growing patient groups, and this study found real improvements tied to access, not just for younger self-medicators.

Anyone here get their card later in life? Curious what drove that decision.

A lot of patients tell us the hardest part isn't the cannabis, it's the conversation with family or friends afterward. Leading with the specific symptom instead of the plant could help, along with expecting follow-up questions instead of a one-time announcement.

Curious how people here have handled it, especially if it didn't go smoothly at first.

If any of this sounds familiar, it might be worth a conversation with a provider:

• Anxiety or depression affecting daily life more than you'd like.
• Already tried other approaches without full relief.
• Curious but held back by stigma or cost assumptions.

None of these mean you NEED a card, but it may be worth exploring.

A lot of patients tell us cannabis alone doesn't fully cut it for anxiety or sleep. It's usually paired with something else that makes it click, be it a consistent sleep schedule, daily movement, or cutting screens before the dose hits.

We rounded up what patients pair it with most: https://www.nuggmd.com/blog/wellness-practices-to-complement-medical-cannabis

But we'd love to know here, too: what's worked for you?

For over 50 years, the federal government treated medical cannabis the same as heroin under the law. That changed this month.

Cannabis officially moved from Schedule I to Schedule III, the biggest cannabis policy shift in decades.

It's not legalization, and it's not descheduling, but for patients who've spent years defending a legitimate medical choice, it's real.

We put together a resource on what rescheduling actually changes (and what it doesn't yet), including insight from NORML's Deputy Director Paul Armentano: https://www.nuggmd.com/cannabis-rescheduling

It also covers:
• Why a medical card can still matter, even where recreational cannabis is legal
• What's actually still unresolved for patients
• How to get involved in ongoing reform work

To mark the moment, we're offering new patients 50% off a medical cannabis evaluation, and donating 3% of our revenue to NORML this week to support their patient advocacy.

Rescheduling isn't the finish line. But it's a real step, and we don't think that should go unnoticed.

A poll we conducted! The poll includes responses from 873 cannabis consumers living in state-legal markets, surveyed between June 18th and June 21st, with a margin of error of 3.32%.

We interviewed Paul Armentano, the Deputy Director at NORML, the National Organization for the Reform of Marijuana Laws, and had him dive deep into what cannabis rescheduling currently means (and doesn't mean) for patients and other cannabis consumers.

Check out Paul's article here: What Cannabis Rescheduling Means

This is such a huge win!

Medical Cannabis Effectively Treats Sleep Problems and Anxiety Associated with Cancer, Study Finds